SCHEMBL6284564

SCHEMBL6284564

N#Cc1cccc(NC(=O)Nc2ccc(S(=O)(=O)Cl)cc2)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.72
MEN1 O00255 3/20 0.72
KMT2A Q03164 3/20 0.72
ALDH1A1 P00352 2/20 0.72
KCNJ6 P48051 1/20 0.57
KCNJ5 P48544 1/20 0.57
KCNJ3 P48549 1/20 0.57
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
NSD2 O96028 1/20 0.56
GAA P10253 1/20 0.55
ALOX15 P16050 1/20 0.55
CASP7 P55210 1/20 0.55
HSD17B10 Q99714 1/20 0.55
CA12 O43570 2/20 0.55
CA1 P00915 2/20 0.55
CA2 P00918 2/20 0.55
CA9 Q16790 2/20 0.55
GRM4 Q14833 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13196624 0.86 CA2 (0.74) MAPTMEN1KMT2AALDH1A1KCNJ6
SCHEMBL2762003 0.84 MAPT (0.68) MAPTMEN1KMT2AALDH1A1KCNJ6
SCHEMBL7248947 0.84 MAPT (1.00) MAPTMEN1KMT2AALDH1A1KCNJ6
SCHEMBL29580531 0.84 MAPT (0.87) MAPTMEN1KMT2AALDH1A1KCNJ6
SCHEMBL30606801 0.84 MAPT (0.87) MAPTMEN1KMT2AALDH1A1KCNJ6
SCHEMBL2762707 0.80 CA2 (0.64) MAPTMEN1KMT2AALDH1A1CA12
SCHEMBL6280104 0.80 KMT2A (0.62) MAPTMEN1KMT2AALDH1A1KCNJ6
SCHEMBL24987217 0.80 MAPT (0.80) MAPTMEN1KMT2AALDH1A1KCNJ6
SCHEMBL6585108 0.80 MAPT (0.80) MAPTMEN1KMT2AALDH1A1KCNJ6
SCHEMBL4117070 0.80 MAPT (0.80) MAPTMEN1KMT2AALDH1A1KCNJ6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949567-B2 Compounds for the treatment of protozoal diseases 4SC AG (DE) 2005-09-27 US disclosed
EP-1395548-A1 DERIVATIVES OF DIPHENYLUREA, DIPHENYLOXALIC ACID DIAMIDE AND DIPHENYLSULFURIC ACID DIAMIDE AND THEIR USE AS MEDICAMENTS 4SC AG (DE) 2004-03-10 EP disclosed
US-20030119876-A1 Compounds for the treatment of protozoal diseases 4SC AG (DE) 2003-06-26 US disclosed
US-20020165236-A1 Compounds for the treatment of protozoal diseases 4SC AG (DE) 2002-11-07 US disclosed
WO-2002070467-A1 DERIVATIVES OF DIPHENYLUREA, DIPHENYLOXALIC ACID DIAMIDE AND DIPHENYLSULFURIC ACID DIAMIDE AND THEIR USE AS MEDICAMENTS 4SC AG (DE) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165236-A1 Compounds for the treatment of protozoal diseases PKD2, PPOX, PKD1 MAPT 2767/4885MEN1 2642/4885KMT2A 2215/4885
US-20030119876-A1 Compounds for the treatment of protozoal diseases CLIC1, PKD2, PKD1 MAPT 2803/4885MEN1 1654/4885KMT2A 3794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.